ESTRO 36 Abstract Book

S629 ESTRO 36 2017 _______________________________________________________________________________________________

RT indications and targets were based on tumors characteristics pre-NCT. More advanced disease at the time of diagnosis and age were the main determinants to define RT to nodal targets independently of NCT response. EP-1167 Accelerated Partial Breast Irradiation: A single center analysis. K. Nugent 1 , D. Kelly 2 , J. McCaffrey 3 , M. Maher 4 1 St Lukes Radiation Network, Radiation Oncology, Dublin, Ireland 2 Cork University Hospital, Medical Oncology, Cork, Ireland 3 Mater Misericordiae University Hospital, Medical Oncology, Dublin 6, Ireland 4 Mater Misericordiae University Hospital, Radiation Oncology, Dublin 6, Ireland Purpose or Objective Our objective was to analyse the use of adjuvant accelerated partial breast radiation (APBI) at our center over a ten year period. We calculated the local recurrence rates, median follow up and overall survival in breast cancer patients who received APBI from 2006 to 2016 . In this retrospective cohort, we obtained the average tumour size, histology grade, hormone status and lymphovascular invasion (LVI) presence in order to review the breast cancer characteristics of the patients we selected to treat with this modality. Material and Methods We conducted a single institution retrospective review of all adjuvant breast cancer patients who received APBI from between January 2006 to September 2016 . Patients were identified from a prospectively-maintained dataset of all patients commencing ABPI. A retrospective chart review was conducted as to determine long term follow up outcomes. The following patient details were recorded: median follow up time, demographics, histology, node status, surgery type, adjuvant treatment and local recurrence. Primary outcome was loco-regional recurrence noting if recurrences occurred within the treated breast quadrant. Results During this period a total of 106 procedures were carried out. The average mean age at time of treatment was 68.2 years. The mean tumour size was 14.65mm, all were estrogen receptor positive and node negative. LVI was present in 8% of the patient cohort. Median follow up was 65 months. The local recurrence rate within the treated breast quadrant was 1.8% (95 CI 0.42-2.44) while the local recurrence rate within the ipsilateral breast was 2.8% (95 CI 1.2-3.3). Overall survival was 97%. Conclusion Our findings suggest that APBI is a reasonable adjuavant option for selected low risk breast cancer patients. EP-1168 male breast cancer; a review of patients treated from 2004 - 2013 (10yrs) P. Scott 1 , V. Vanderpuye 1 , J. Yarney 1 , N. Aryeetey 1 , H. Ayettey 1 , M. Dadzie 1 , Z. Meles 1 1 Korlebu Teaching Hospital, National Centre for radiotherapy and Nuclear Medicine, ACCRA, Ghana Purpose or Objective Male breast carcinoma (MBC) is rare, and the incidence varies worldwide. It accounts for about 1% of all breast cancers. Due to the rarity of this disease, there is a lack of prospective clinical trials to define its optimum treatment. Current data consists mostly of small retrospective studies, hence treatment generally follows the principles established for that of female breast cancer. The purpose of this study was to review and analyse breast cancer in men managed from 2004 to 2013. Material and Methods

Men with histologically confirmed breast cancer from 2004–2013 were studied. Information regarding patient demographics, presenting symptoms, tumor characteristics, treatment and outcomes were analysed. Results Over the 10 year period, 41 patients were studied, making 1.6% of all breast cancer cases managed. Median age at diagnosis was 66 years, ranging 36-89. Majority, 87.8%, self-detected a lump in the breast. The median time from onset of symptoms to diagnosis was 12 months, ranging 3–48. The commonest histology was invasive ductal carcinoma ,70.7%. Stage III disease represented 47.58%, while stage I, II and IV disease made up 7.32%, 19.61% and 25.49% respectively Hormone receptor (HR) status was unknown in 63.4%, 14.6% were estrogen receptor (ER) only positive, 7.3% were progesterone receptor (PR) only positive, 4.9% were ER and PR positive, and 9.8% were ER and PR negative. Of those who had their HR status checked, 73.2% were HR positive. Modified radical mastectomy was the most common surgical procedure, 46.3%, mastectomy only in 14.6% and breast conservation in 7.3%. 46.3% of patients received adjuvant radiotherapy. 48.8% did not receive adjuvant radiotherapy because they were metastatic, defaulted or presented late after the surgery. 40.3% received chemotherapy in adjuvant, neoadjuvant or metastatic setting. Hormone receptor positive patients had Tamoxifen. Median follow up duration was 7 months, ranging 0-64. Median survival was 13 months and 5 year overall survival of 2%. Conclusion MBC makes up 1.6% of all breast cancer presenting to our centre, consistent with worldwide findings of about 1%. Majority presented with locally advanced or metastatic disease. Outcomes are poor and could be due to late presentation. Screening programs may translate into better outcomes. MBC is frequently hormone receptor positive and may be more sensitive to hormonal therapy, hence receptor status testing is recommended. Low survival and poor follow up made disease free survival difficult to determine. EP-1169 Preoperative CT scan in tumor bed delineation after breast conserving surgery and oncoplasty T. Saxena 1 , V. Goel 1 , G. Kadyaprath 2 , D. Arora 3 , A.K. Verma 1 , P. Agarwal 1 , P. Kumar 1 , J. Jain 1 , R. Shukla 1 , P. Kumar 3 , A. Masanta 3 , T.R. Singh 4 , R. Kaur 4 , A.K. Anand 1 1 Max Hospital- Delhi- India, Radiation Oncology, Delhi, India 2 Max Hospital- Delhi- India, Surgical Oncology, Delhi, India 3 Max Hospital- Delhi- India, Medical Physics, Delhi, India 4 Max Hospital- Delhi- India, Radiation Therapy Technologist, Delhi, India Purpose or Objective Background: Tumor bed (TB) boost, in addition to whole breast radiation therapy (WBRT) improves local control rates as compared to WBRT alone after breast conserving surgery (BCS). There are several pitfalls in localizing TB accurately. Surgical clips are generally placed over pectoralis muscle, even if the tumor is superficial and hence not truly representative and there is always a concern of clip migration. Mammogram and MR mammogram are not quite useful as they are done in a non-anatomic position. Problem of accurate TB identification is further compounded in patients with oncoplastic reconstruction. In oncoplastic surgeries (OPS), scar is often not representative of tumor location. Seroma cavity is generally obliterated by tissue repositioning.